Reactions 1704, p330 - 2 Jun 2018 Intraocular pressure elevation: 8 case reports In a retrospective study, eight patients (four men and four women), aged 65 84 years, were described, who developed elevated intraocular pressure (IOP) following the administration of ranibizumab [Lucentis] for age-related macular degeneration (AMD). The patients with AMD received intravitreal ranibizumab 0.5mg in 0.05mL injections. The patients had a history of glaucoma (four patients) and ocular hypertension (one patient). After three to eight injections over three to twelve months, seven patients experienced IOP elevation, and one patient developed IOP elevation at four follow-up. The patients were treated with acetazolamide, brimonidine/ timolol, apraclonidine, brimonidine and/or pilocarpine. Six patient underwent selective laser trabeculoplasty, trabeculectomy, cyclodiode laser surgery or combined phacoemulsification and viscocanalostomy. After the procedure, their IOP had improved. Six patients were continued on ranibizumab injections after the procedure and their IOP remained controlled. Author comment: "Intravitreal ranibizumab injections are associated with sustained [intraocular pressure] elevation in some eyes." Reis GMSM, et al. Incidence of intraocular pressure elevation following intravitreal ranibizumab (Lucentis) for age-related macular degeneration. Journal of Current Glaucoma Practice 11: 3-7, No. 1, Jan-Apr 2017. Available from: URL: http://doi.org/10.5005/jp-journals-10008-1213 - Australia 803323602 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud